<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pharminsider.com/articles/us-fda-closes-natco-pharma-s-visakhapatnam-plant-inspection-as-vai</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T09:52:05.781Z</news:publication_date>
      <news:title>US FDA closes Natco Pharma&apos;s Visakhapatnam plant inspection as VAI</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/white-house-pulls-heidi-overton-s-fda-nomination-hours-before-senate-vote</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T08:55:05.160Z</news:publication_date>
      <news:title>White House Pulls Heidi Overton&apos;s FDA Nomination Hours Before Senate Vote</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-summit-s-ivonescimab-over-missed-survival-endpoint</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T07:34:39.191Z</news:publication_date>
      <news:title>FDA Rejects Summit&apos;s Ivonescimab Over Missed Survival Endpoint</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/tesorai-raises-5-3m-seed-to-mine-raw-proteomics-spectra-with-ai</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T07:34:39.191Z</news:publication_date>
      <news:title>Tesorai Raises $5.3M Seed to Mine Raw Proteomics Spectra with AI</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/cretostimogene-cuts-bladder-cancer-relapse-risk-68-in-phase-3</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T07:34:39.191Z</news:publication_date>
      <news:title>Cretostimogene Cuts Bladder Cancer Relapse Risk 68% in Phase 3</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/astrazeneca-cuts-600-us-sales-jobs-in-1-5b-savings-push</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>AstraZeneca Cuts 600 US Sales Jobs in $1.5B Savings Push</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-sanofi-s-infilbray-first-therapy-for-gaucher-type-3-brain-symptoms</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>FDA Approves Sanofi&apos;s Infilbray, First Therapy for Gaucher Type 3 Brain Symptoms</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/standalone-device-strategy-demands-early-fda-ema-engagement</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>Standalone Device Strategy Demands Early FDA, EMA Engagement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/mhra-launches-advancegxp-as-ema-clarifies-equivalence-testing</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>MHRA Launches AdvanceGxP as EMA Clarifies Equivalence Testing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/marrow-therapeutics-exits-stealth-with-173m-and-an-sirna-shot-at-sickle-cell</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>Marrow Therapeutics Exits Stealth With $173M and an siRNA Shot at Sickle Cell</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/isomorphic-labs-banks-5-billion-series-c-in-ai-drug-discovery-push</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:12:53.930Z</news:publication_date>
      <news:title>Isomorphic Labs Banks $5 Billion Series C in AI Drug Discovery Push</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/wegovy-pill-holds-72-8-of-oral-obesity-market-as-foundayo-scripts-hit-record</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T04:01:26.257Z</news:publication_date>
      <news:title>Wegovy pill holds 72.8% of oral obesity market as Foundayo scripts hit record</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/chmp-backs-baxfendy-revives-aumseqa-flags-mounjaro-contraceptive-risk</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T04:01:26.257Z</news:publication_date>
      <news:title>CHMP Backs Baxfendy, Revives Aumseqa, Flags Mounjaro-Contraceptive Risk</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-demanding-survival-data-summit-did-not-have</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T04:01:26.257Z</news:publication_date>
      <news:title>FDA Rejects Ivonescimab, Demanding Survival Data Summit Did Not Have</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ucla-stem-cell-vesicles-keep-55-of-mice-diabetes-free-for-90-days</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T04:01:26.257Z</news:publication_date>
      <news:title>UCLA Stem Cell Vesicles Keep 55% of Mice Diabetes-Free for 90 Days</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/sone-ve-receives-fda-priority-review-for-advanced-gastric-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T03:36:13.496Z</news:publication_date>
      <news:title>Sone-Ve receives FDA priority review for advanced gastric cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/j-j-pays-2-2b-upfront-for-ollin-s-vabysmo-rival-oln324</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T03:36:13.496Z</news:publication_date>
      <news:title>J&amp;J Pays $2.2B Upfront for Ollin&apos;s Vabysmo Rival OLN324</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-seeks-authority-to-deem-prescription-drug-ads-misbranded</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T03:36:13.496Z</news:publication_date>
      <news:title>FDA seeks 2027 authority to deem prescription-drug ads misbranded</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/glp-1-spend-eats-14-7-of-multiemployer-plan-claims-masks-care-value</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>GLP-1 Spend Eats 14.7% of Multiemployer Plan Claims, Masks Care Value</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-roche-s-wilserdly-a-month-ahead-of-deadline</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>FDA clears Roche&apos;s Wilserdly a month ahead of deadline</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/blackstone-puts-1-5b-into-pfizer-obesity-drug-buys-no-rights</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>Blackstone Puts $1.5B Into Pfizer Obesity Drug, Buys No Rights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-opens-its-review-dossiers-to-foreign-regulators</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>FDA Opens Its Review Dossiers to Foreign Regulators</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/isomorphic-labs-signs-merck-for-ai-designed-oncology-drug-two-days-after-5b-rais</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>Isomorphic Labs signs Merck for AI-designed oncology drug two days after $5B raise</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ichnos-glenmark-files-fda-ind-for-pentaspecific-solid-tumour-drug-isb-2301</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T02:53:48.910Z</news:publication_date>
      <news:title>Ichnos Glenmark Files FDA IND for Pentaspecific Solid Tumour Drug ISB 2301</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-regeneron-s-livsayis-first-sirna-treatment-for-gmg</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T22:37:41.895Z</news:publication_date>
      <news:title>FDA clears Regeneron&apos;s Livsayis, first siRNA treatment for gMG</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/inovio-to-ship-voceryq-within-60-days-after-fda-accelerated-approval</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:23:00.226Z</news:publication_date>
      <news:title>Inovio to Ship VOCERYQ Within 60 Days After FDA Accelerated Approval</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-warning-letter-hits-alkem-s-daman-plant-source-of-45-of-us-sales</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:23:00.226Z</news:publication_date>
      <news:title>FDA Warning Letter Hits Alkem&apos;s Daman Plant, Source of 45% of US Sales</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-issues-warning-letter-for-alkem-s-daman-plant-after-oai-inspection</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:23:00.226Z</news:publication_date>
      <news:title>FDA issues warning letter for Alkem&apos;s Daman plant after OAI inspection</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/humanitas-exits-stealth-with-lsu-deepdrug-license-and-104-program-book</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T20:40:38.788Z</news:publication_date>
      <news:title>Humanitas exits stealth with LSU DeepDrug license and 104-program book</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-accepts-second-evotecbms-molecular-glue-ind-shares-up-2</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T20:40:38.788Z</news:publication_date>
      <news:title>FDA Accepts Second Evotec–BMS Molecular Glue IND; Shares Up 2%</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-livsayis-for-achr-positive-generalised-myasthenia-gravis</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T20:40:38.788Z</news:publication_date>
      <news:title>FDA approves Livsayis for AChR-positive generalised myasthenia gravis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ciplas-new-york-plant-gets-fda-no-action-classification</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:40:13.074Z</news:publication_date>
      <news:title>Cipla’s New York plant gets FDA no-action classification</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-perioperative-imfinzi-padcev-regimen-in-bladder-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:40:13.074Z</news:publication_date>
      <news:title>FDA approves perioperative Imfinzi-Padcev regimen in bladder cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-in-summits-egfr-nsclc-application</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:40:13.074Z</news:publication_date>
      <news:title>FDA rejects ivonescimab in Summit’s EGFR-NSCLC application</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/nelkarmi-wins-accelerated-fda-approval-gsk-shares-hold-at-gbx1-871</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:40:13.074Z</news:publication_date>
      <news:title>Nelkarmi wins accelerated FDA approval; GSK shares hold at GBX1,871</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-gsks-nelkarmi-for-pretreated-alk-positive-lung-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:40:13.074Z</news:publication_date>
      <news:title>FDA approves GSK’s Nelkarmi for pretreated ALK-positive lung cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-roche-s-wilserdly-for-esr1-mutate</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:40:59.026Z</news:publication_date>
      <news:title>FDA Clears Cosentyx for Polymyalgia Rheumatica, Roche&apos;s Wilserdly for ESR1-Mutated Breast Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/terumo-bct-automates-engineered-til-production-with-quantum-flex</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:53:11.065Z</news:publication_date>
      <news:title>Terumo BCT Automates Engineered TIL Production with Quantum Flex</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/alcohol-cuts-anti-pd-1-efficacy-roughly-50-in-mouse-cancer-models</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:53:11.065Z</news:publication_date>
      <news:title>Alcohol Cuts Anti-PD-1 Efficacy Roughly 50% in Mouse Cancer Models</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-gsk-s-nelkarmi-second-asset-from-10-6b-nuvalent-deal</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:53:11.065Z</news:publication_date>
      <news:title>FDA Clears GSK&apos;s Nelkarmi, Second Asset from $10.6B Nuvalent Deal</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-agrees-200-patient-phase-3-design-for-rec-4881-in-fap</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T05:42:53.323Z</news:publication_date>
      <news:title>FDA agrees 200-patient Phase 3 design for REC-4881 in FAP</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-roche-s-wilserdly-for-advanced-breast-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T05:42:53.323Z</news:publication_date>
      <news:title>FDA Clears Roche&apos;s Wilserdly for Advanced Breast Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-moves-to-withdraw-approval-of-flolipid-liquid-simvastatin</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T05:42:53.323Z</news:publication_date>
      <news:title>FDA Moves to Withdraw Approval of FloLipid Liquid Simvastatin</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-grants-gsk-accelerated-approval-for-alk-inhibitor-nelkarmi</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T05:42:53.323Z</news:publication_date>
      <news:title>FDA grants GSK accelerated approval for ALK inhibitor Nelkarmi</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-11th-us-indication</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T05:42:53.323Z</news:publication_date>
      <news:title>FDA Clears Cosentyx for Polymyalgia Rheumatica, 11th US Indication</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-hands-cipla-s-invagen-new-york-plant-no-action-indicated-status</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:23:10.362Z</news:publication_date>
      <news:title>FDA Hands Cipla&apos;s InvaGen New York Plant &apos;No Action Indicated&apos; Status</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clinical-pharmacology-mapp-takes-effect-with-four-review-areas</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:23:10.362Z</news:publication_date>
      <news:title>FDA clinical pharmacology MAPP takes effect with four review areas</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-two-tubeless-insulin-systems-medtronic-buys-contego-for-380m</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:23:10.362Z</news:publication_date>
      <news:title>FDA Clears Two Tubeless Insulin Systems; Medtronic Buys Contego for $380M</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-j-j-bets-3-3b-on-eye-biotech-ollin</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:23:10.362Z</news:publication_date>
      <news:title>FDA Rejects Ivonescimab; J&amp;J Bets $3.3B on Eye Biotech Ollin</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/marrow-therapeutics-raises-173m-for-bone-marrow-targeted-therapies</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Marrow Therapeutics raises $173M for bone marrow-targeted therapies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/flagship-puts-100m-into-first-non-u-s-company-creation-lab-in-london</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Flagship Puts £100M Into First Non-U.S. Company Creation Lab in London</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ensol-bio-science-targets-kosdaq-transfer-on-fda-fast-track-and-obesity-licensin</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Ensol Bio Science Targets KOSDAQ Transfer on FDA Fast-Track and Obesity Licensing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/immunobrain-s-anti-pd-l1-antibody-cuts-alzheimer-s-damage-biomarkers-in-phase-ib</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>ImmunoBrain&apos;s Anti-PD-L1 Antibody Cuts Alzheimer&apos;s Damage Biomarkers in Phase Ib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-opens-its-approval-files-to-world-regulators-with-grdp</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FDA Opens Its Approval Files to World Regulators With GRDP</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/oyster-therapeutics-lands-60m-to-take-protein-degraders-into-the-brain</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Oyster Therapeutics Lands $60M to Take Protein Degraders Into the Brain</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-secures-up-to-1-5b-for-berobenatide-trials</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Pfizer secures up to $1.5B for berobenatide trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/bora-books-437m-cdmo-contracts-defers-25-batches-on-fda-upgrades</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Bora Books $437M CDMO Contracts, Defers 25 Batches on FDA Upgrades</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-s-bourla-chinese-drugmakers-will-be-my-main-rivals</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Pfizer&apos;s Bourla: Chinese drugmakers will be my main rivals by 2030</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/trump-withdraws-overton-widening-fda-leadership-gap-for-sponsors</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Trump withdraws Overton, widening FDA leadership gap for sponsors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-pebrilzo-but-settlement-delays-biocons-u-s-launch</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FDA approves Pebrilzo, but settlement delays Biocon’s U.S. launch</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/nih-to-replace-disease-based-trial-funding-with-five-trial-type-nofos</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>NIH to replace disease-based trial funding with five trial-type NOFOs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/antibacterial-pipeline-shrinks-from-97-to-90-and-ai-resistance-tools-inherit-bad</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Antibacterial pipeline shrinks from 97 to 90, and AI resistance tools inherit bad data</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/eu-regulators-weigh-streamlining-combination-product-reviews</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>EU regulators weigh streamlining combination product reviews</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-pays-330m-for-three-starna-in-vivo-car-t-programs</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Pfizer Pays $330M for Three Starna In Vivo CAR-T Programs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/folr1-adc-resensitizes-colorectal-tumors-to-anti-pd-1-in-mice</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FOLR1 ADC resensitizes colorectal tumors to anti-PD-1 in mice</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/help-votes-wednesday-on-overton-as-fda-shelves-cnpv</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>HELP votes Wednesday on Overton as FDA shelves CNPV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/windward-bio-raises-225-million-in-ipo-and-placement</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Windward Bio raises $225 million in IPO and placement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/j-j-pays-2-2-billion-for-ollin-mounting-direct-challenge-to-roche-s-vabysmo</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>J&amp;J Pays $2.2 Billion for Ollin, Mounting Direct Challenge to Roche&apos;s Vabysmo</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/glenmark-files-us-fda-ind-for-three-target-oncology-drug-isb-2301</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>Glenmark files US FDA IND for three-target oncology drug ISB 2301</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-greenlights-roche-s-wilserdly-oncology-wave</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FDA rejects ivonescimab, greenlights Roche&apos;s Wilserdly in November oncology wave</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-china-developed-ivonescimab-on-overall-survival-grounds</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FDA rejects China-developed Ivonescimab on overall-survival grounds</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-grants-gsks-neladalkib-accelerated-approval-for-alk-lung-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmInsider</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T03:48:12.231Z</news:publication_date>
      <news:title>FDA grants GSK’s neladalkib accelerated approval for ALK lung cancer</news:title>
    </news:news>
  </url>
</urlset>
